Literature DB >> 26249221

Increased Galectin-9 Concentration and Number of CD4+Foxp3high+Cells in Bronchoalveolar Lavage Fluid of Patients with Cryptogenic Organizing Pneumonia.

Shigeki Katoh1, Masaki Ikeda2, Hiroki Shimizu2, Masaaki Abe2, Yoshihiro Ohue2, Keiji Mouri2, Yoshihiro Kobashi2, Mikio Oka2.   

Abstract

PURPOSE: Galectin-9 (Gal-9) is a β-galactoside-binding protein that exhibits various biological reactions, such as chemoattraction, cell aggregation, and apoptosis. Recent studies demonstrated that Gal-9 has a role as an immunomodulator in excessive immunological reactions by expanded regulatory T cells (Tregs). We examined the role of Gal-9 in the pathogenesis of one of the major idiopathic interstitial pneumonias, cryptogenic organizing pneumonia (COP) as compared with idiopathic pulmonary fibrosis (IPF).
METHODS: Gal-9, transforming growth factor-β1, and interleukin (IL)-10 levels in the bronchoalveolar lavage fluid (BALF) of patients with COP and IPF were estimated by enzyme-linked immunosorbent assay. Forkhead box protein 3 (Foxp3) expressing Tregs were evaluated by flow cytometry. The effect of Gal-9 on interactions between human lung fibroblast cells and hyarulonan was assessed in vitro.
RESULTS: Gal-9 and IL-10 levels in the BALF were significantly higher in patients with COP than in patients with IPF. The number of CD4+Foxp3high+cells was significantly higher in the BALF of patients with COP than in those with IPF. Gal-9 levels significantly correlated with the absolute number of CD4+CD25+Foxp3+cells or CD4+Foxp3high+cells, but not with the absolute number of CD4+CD25+Foxp3-cells, in the BALF of patients with COP. Gal-9 suppressed the CD44-dependent interaction of human lung fibroblast cells with hyarulonan in a dose-dependent manner.
CONCLUSIONS: Our findings suggest that increased Gal-9 levels in the lung have a protective role against lung inflammation and fibrosis in patients with COP through the induction of Tregs in the lung and CD44-dependent inhibitory effects on lung fibroblast cells.

Entities:  

Keywords:  Bronchoalveolar lavage fluid; Cryptogenic organizing pneumonia; Galectin-9; Lung fibrosis; Regulatory T cells

Mesh:

Substances:

Year:  2015        PMID: 26249221     DOI: 10.1007/s00408-015-9775-x

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  24 in total

Review 1.  Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self.

Authors:  Shimon Sakaguchi
Journal:  Nat Immunol       Date:  2005-04       Impact factor: 25.606

2.  Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells.

Authors:  Chuan Wu; Theresa Thalhamer; Rafael F Franca; Sheng Xiao; Chao Wang; Chie Hotta; Chen Zhu; Mitsuomi Hirashima; Ana C Anderson; Vijay K Kuchroo
Journal:  Immunity       Date:  2014-07-24       Impact factor: 31.745

3.  Possible regulatory role of galectin-9 on Ascaris suum-induced eosinophilic lung inflammation in mice.

Authors:  Shigeki Katoh; Souichi Oomizu; Toshiro Niki; Hiroki Shimizu; Yasushi Obase; Masataka Korenaga; Mikio Oka; Mistuomi Hirashima
Journal:  Int Arch Allergy Immunol       Date:  2012-05-15       Impact factor: 2.749

Review 4.  Regulatory T cells and autoimmune disease.

Authors:  Silke Paust; Harvey Cantor
Journal:  Immunol Rev       Date:  2005-04       Impact factor: 12.988

5.  Imbalance between subpopulations of regulatory T cells in COPD.

Authors:  Jia Hou; Yongchang Sun; Yu Hao; Jie Zhuo; Xiaofang Liu; Peng Bai; Junyan Han; Xiwei Zheng; Hui Zeng
Journal:  Thorax       Date:  2013-06-07       Impact factor: 9.139

6.  A possible role of galectin-9 in the pulmonary fibrosis of patients with interstitial pneumonia.

Authors:  Nobuhiro Matsumoto; Shigeki Katoh; Shigehisa Yanagi; Yasuji Arimura; Masatoshi Tokojima; Masaki Ueno; Mitsuomi Hirashima; Masamitsu Nakazato
Journal:  Lung       Date:  2013-01-16       Impact factor: 2.584

7.  CD4+CD25+Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury.

Authors:  Franco R D'Alessio; Kenji Tsushima; Neil R Aggarwal; Erin E West; Matthew H Willett; Martin F Britos; Matthew R Pipeling; Roy G Brower; Rubin M Tuder; John F McDyer; Landon S King
Journal:  J Clin Invest       Date:  2009-09-21       Impact factor: 14.808

8.  Analysis of regulatory T cell associated forkhead box P3 expression in the lungs of patients with sarcoidosis.

Authors:  F Idali; J Wahlström; C Müller-Suur; A Eklund; J Grunewald
Journal:  Clin Exp Immunol       Date:  2008-02-14       Impact factor: 4.330

9.  Galectin-9 inhibits CD44-hyaluronan interaction and suppresses a murine model of allergic asthma.

Authors:  Shigeki Katoh; Naoki Ishii; Atsuya Nobumoto; Keisuke Takeshita; Shu-Yan Dai; Rika Shinonaga; Toshiro Niki; Nozomu Nishi; Akira Tominaga; Akira Yamauchi; Mitsuomi Hirashima
Journal:  Am J Respir Crit Care Med       Date:  2007-04-19       Impact factor: 21.405

10.  Increased levels of plasma galectin-9 in patients with influenza virus infection.

Authors:  Shigeki Katoh; Masaki Ikeda; Hiroki Shimizu; Keiji Mouri; Yasushi Obase; Yoshihiro Kobashi; Kiyoyasu Fukushima; Mistuomi Hirashima; Mikio Oka
Journal:  Tohoku J Exp Med       Date:  2014-04       Impact factor: 1.848

View more
  3 in total

1.  Hashimoto's thyroiditis-induced cryptogenic organizing pneumonia: A case report.

Authors:  Litao Guo; Bo Chen; Lei Zhang; Yuan Deng; Hao Li; Qin Dong Shi
Journal:  Exp Ther Med       Date:  2019-10-30       Impact factor: 2.447

2.  Aberrantly Expressed Galectin-9 Is Involved in the Immunopathogenesis of Anti-MDA5-Positive Dermatomyositis-Associated Interstitial Lung Disease.

Authors:  Lin Liang; Ya-Mei Zhang; Ya-Wen Shen; Ai-Ping Song; Wen-Li Li; Li-Fang Ye; Xin Lu; Guo-Chun Wang; Qing-Lin Peng
Journal:  Front Cell Dev Biol       Date:  2021-03-25

3.  Circulating Levels of PD-L1, TIM-3 and MMP-7 Are Promising Biomarkers to Differentiate COVID-19 Patients That Require Invasive Mechanical Ventilation.

Authors:  Leslie Chavez-Galan; Andy Ruiz; Karen Martinez-Espinosa; Hiram Aguilar-Duran; Martha Torres; Ramces Falfan-Valencia; Gloria Pérez-Rubio; Moises Selman; Ivette Buendia-Roldan
Journal:  Biomolecules       Date:  2022-03-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.